Literature DB >> 15899778

Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact.

Deniz L Aslan1, H Evin Gulbahce, Stefan E Pambuccian, J Carlos Manivel, Jose Jessurun.   

Abstract

The aim of the present study was to evaluate the usefulness of immunohistochemical markers in the differential diagnosis of pulmonary neuroendocrine tumors with particular emphasis on the preservation of immunoreactivity in areas showing crush artifacts. Specimens from 9 carcinoid tumors (CTs) and 13 small cell carcinomas (SCCs) with crush artifact were stained with antibodies to Ki-67, chromogranin A, synaptophysin, and cytokeratin. The immunoreactivity was well preserved in the crushed areas. Ki-67 was expressed in the crushed areas of all SCCs. Reactivity was diffuse or at least present in 25% of the crushed areas. In contrast, the immunoreactive areas in CTs never exceeded 10%. Immunoreactivity for Ki-67, synaptophysin, chromogranin A, and cytokeratin is well preserved in tissue with crush artifacts and can be interpreted reliably. The diagnosis of SCC should be questioned if fewer than 25% of cells show reactivity for Ki-67.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899778     DOI: 10.1309/QYV0-5VGE-GKUL-2RTT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

1.  JPEG2000 for automated quantification of immunohistochemically stained cell nuclei: a comparative study with standard JPEG format.

Authors:  Marylène Lejeune; Carlos López; Ramón Bosch; Anna Korzyńska; Maria-Teresa Salvadó; Marcial García-Rojo; Urszula Neuman; Łukasz Witkowski; Jordi Baucells; Joaquín Jaén
Journal:  Virchows Arch       Date:  2010-11-18       Impact factor: 4.064

2.  Ki-67 expression in pulmonary tumors-reply.

Authors:  Mark Kriegsmann; Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2016-10

3.  Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice.

Authors:  Chi H L Dinh; Yinghua Yu; Alexander Szabo; Qingsheng Zhang; Peng Zhang; Xu-Feng Huang
Journal:  J Histochem Cytochem       Date:  2016-02-26       Impact factor: 2.479

4.  Ki-67 expression in pulmonary tumors.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

5.  Tumor cell proliferation, proliferative index and mitotic count in lung cancer.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 6.  Carcinoid tumor of the middle ear: a case report and review of literature.

Authors:  Guo Liu; Fei Chen; Jin-Nan Li; Shi-Xi Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

7.  Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Mauro Papotti; Luisella Righi; Gaia Gatti; Patrick Maisonneuve; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-01-04       Impact factor: 4.064

8.  KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?

Authors:  Federica Grillo; Luca Valle; Diego Ferone; Manuela Albertelli; Maria Pia Brisigotti; Giuseppe Cittadini; Alessandro Vanoli; Roberto Fiocca; Luca Mastracci
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

9.  Surgical treatment by partial petrosectomy for a middle-ear carcinoid with progressive extension: a case report and review of the literature.

Authors:  Mitsuhiro Aoki; Keisuke Mizuta; Natsuko Ueda; Nansei Yamada; Yatsuji Ito; Hiroki Kato; Yoshinobu Hirose
Journal:  Int J Otolaryngol       Date:  2010-06-06

10.  Small-cell lung carcinoma with long-term survival: A case report.

Authors:  Kazumi Nishino; Fumio Imamura; Toru Kumagai; Junji Uchida; Yuki Akazawa; Takako Okuyama; Yasuhiko Tomita
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.